The Budget Impact Of Introducing A PD-L1 Assay To Select Patients With Metastatic Nsclc Who Are Potential Candidates For Treatment With Immune Checkpoint Inhibitors

Sheppard, B. L.; Ahlsten, Manuel; Paolini, Davide; Xenakis, James G.; Zhang, W

doi:10.1016/j.jval.2017.08.1007

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have highlighted that while molecular testing may enable better treatment selection and savings in the longer term, it is also associated with significant impact on hospital laboratory budgets [78]. As indicated by Sheppard et al [79] utilization of PD-L1 testing decreased treatment costs by 47% but also increased diagnostic costs by e354,783 (2019 SEK 4,4 million) 2 . Chabrol et al [55] analyzed the budgetary impact of PD-L1 testing in second-line therapy for NSCLC from a Brazilian private payer perspective.…”

Section: Health Economicsmentioning

confidence: 99%

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm

Breimer

Nousios

Olsson

et al. 2020

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have received much attention not least for melanoma since the award of the Nobel prize in 2018. Here, we review the current state of knowledge about the use of these monoclonal antibodies (mAbs) in non-small cell lung cancer (NSCLC). These drugs have generally been conditionally approved on limited early data and there are few long-term follow-up data from randomized clinical trials. The effect observed for NSCLC thus far is, on average, moderately better than that obtained with chemotherapy. Severe side-effects are more common than might have been expected. The drugs themselves are expensive and are associated with time-consuming histopathologic testing even though the predictive value of these tests can be discussed. In addition, monitoring for side-effects involves increased workload and budgetary expense for clinical chemistry laboratories. Here, we review and summarize the current knowledge, controversies and ambiguities of ICIs for the treatment of NSCLC.

show abstract

Section: Health Economicsmentioning

confidence: 99%

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm

Breimer

Nousios

Olsson

et al. 2020

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice

Nesline¹,

Knight

Colman

et al. 2020

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: The efficacy of checkpoint inhibitor (CPI) immunotherapy in patients with nonesmall cell lung cancer (NSCLC) is limited by a lack of strongly predictive response markers, subjecting patients to potential underutilization of alternative effective treatments, increased risk for futile care, and unnecessary costs. Here, we characterize the extent to which basic molecular tumor-marker testing has been performed for NSCLC therapy selection in the United States, and compare medical resource utilization and costs in CPI-treated patients versus CPI-eligible patients treated with other therapies. Methods: We identified a cohort of CPI-treated patients with NSCLC and a propensity scoreematched cohort of CPI-eligible patients with NSCLC treated with non-CPI therapies (3095 patients in each group), using US administrative claims data covering the pre-and postinitial FDAapproval period for nivolumab, pembrolizumab, and atezolizumab (October 2012 to September 2017). We describe the utilization of recommended baseline molecular testing for CPI selection (preeindex date for CPI or other anticancer therapy), including programmed death ligand 1 (PD-L1) immunohistochemistry, ALK rearrangement and EGFR mutation testing, and pre-and postindex treatment patterns. All-cause medical resource utilization and semiannual total reimbursement (costs) were compared between CPI-treated and non-CPIetreated patients. Findings: At baseline, in the propensity scoreematched CPI-and noneCPI-treated patient cohorts, mean PD-L1 immunohistochemistry test

show abstract

The Budget Impact Of Introducing A PD-L1 Assay To Select Patients With Metastatic Nsclc Who Are Potential Candidates For Treatment With Immune Checkpoint Inhibitors

Cited by 2 publications

References 0 publications

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm

Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice

Contact Info

Product

Resources

About